Patients with peritoneal mesothelioma appear to be at an increased risk of bowel obstructions either due to disease or perhaps as a consequence of their treatment. They can be caused by adhesions (scar tissue) and/or tumors among other predisposing conditions. Signs of a bowel obstruction include abdominal pain, cessation of bowel movement, absence of bowel […]
Research, Science and Treatments
When patients and their families need help following a diagnosis or throughout treatment, the Meso Foundation is there for them – day or night.
But getting patients and their families through the immediate treatment is only one side of tackling this disease. At the Meso Foundation, we believe that research into new treatments is fundamental to […]
Last week, the Journal of Thoracic Oncology published the results of a study looking into the overexpression of the ephrin B2 receptor (EPHB2) in patients with mesothelioma. The researchers at the New York University Langone Medical Center observed that EPHB2 is overexpressed in all malignant mesothelioma cell lines, but not in benign mesothelial cells. In addition, […]
Personalized medicine is the ability to select a biologic target and direct therapy against this target. It is associated with improved outcomes in a number of tumor types. The most startling was the development of Gleevec which targets CKit in gastrointestinal stromal tumors. The field has since grown by leaps and bounds. We are making […]
By Lee Krug, MD, Memorial Sloan-Kettering Cancer Center
The American Society of Clinical Oncology meeting was held from June 1-4 in Chicago. This is the largest oncology meeting each year with around 30,000 attendees from all over the globe who congregate to discuss the latest research in all cancer types. I thought I would summarize a […]